Vaccine and Immunotherapy Technologies
9-11 April 2008, Canberra

Vaccine and Immunotherapy Technologies brings together eminent experts from around the world for a vibrant and cutting-edge conference program.

The conference provides a balanced and diverse insight into the rapidly evolving scientific area of vaccines and immunotherapy. It showcases the most recent high-tech basic science concepts in vaccine and immunotherapy research, and highlights the challenges of deployment and delivery of vaccines in the real world.

Speakers from Australia, Asia, Europe and the US discuss the many severe research and applied challenges that remain in the fields of vaccines and immunotherapy, but also present current success stories such as the introduction of the first vaccine against cervical cancer.

Vaccine and Immunotherapy Technologies is jointly managed by the Australian Academy of Science and the Australian Academy of Technological Sciences and Engineering.

> > Media releases

Program Organising Committee:

Program

WEDNESDAY 9 APRIL

9.00amWelcome
Professor Kurt Lambeck, PresAA, FRS
Australian Academy of Science
9.05amOpening Address
Senator The Honourable Jan McLucas
Parliamentary Secretary to the Minister for Health and Ageing
9.15amWednesday Plenary Address
Controlling cancer through immunisation – a glass half full?
Professor Ian Frazer, FAA, FTSE
Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland

SESSION 1: Vaccine and immunotherapy super challenges

Chair: Professor Ian Ramshaw
John Curtin School of Medical Research, Australian National University

10.00amAIDS vaccine development: Challenges and opportunities
Dr Wayne Koff
International AIDS Vaccines Initiative, USA
11.00amNew solutions to the challenge of vaccines for tuberculosis
Professor Warwick Britton
Central Clinical School, University of Sydney; Mycobacterial Research Group, The Centenary Institute of Cancer Medicine and Cell Biology
11.30amProspects for the development of an anti-toxic vaccine against malaria
Dr Louis Schofield
The Walter and Eliza Hall Institute of Medical Research, Melbourne
12.00pmProphylactic and therapeutic vaccines against Epstein-Barr virus and its associated cancers
Professor Andy Morgan
School of Medical Sciences, University of Bristol, UK

SESSION 2: Vaccine and immunotherapy super challenges (continued)

Chair: Professor Ian Gust, FTSE
Department of Microbiology and Immunology, University of Melbourne

1.30pmEmerging antigenic mismatch between H5N1 avian influenza field strains and available vaccines
Dr Peter Daniels
CSIRO Australian Animal Health Laboratory
2.00pmDevelopment and application of vaccines for H5N1 avian influenza
Professor Hualan Chen
National Avian Reference Laboratory, Harbin, China
2.30pmHerpes simplex virus vaccine development: Insights and conundrums
Professor Lawrence Stanberry
College of Physicians and Surgeons of Columbia University, USA

SESSION 3: Vaccine and immunotherapy super challenges (continued)

Chair: Professor Kenneth K Wu
National Health Research Institutes, Taiwan

3.30pmDendritic cell immunotherapy to treat patients with persistent hepatitis C virus infection
Professor Eric Gowans
Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne
4.00pmImmunotherapeutic DNA vaccines for HIV: Increased immune function and viral control in the nonhuman primate model for AIDS
Dr Deborah Fuller
Center for Immunology and Microbial Disease Albany Medical College, Albany, USA

THURSDAY 10 APRIL

SESSION 4: Optimising vaccine delivery

Chair: Professor Peter Gray, FTSE
Australian Institute for Bioengineering and Nanotechnology, University of Queensland

8.45amThursday Plenary Address
ISCOMATRIX® adjuvant for prophylactic and therapeutic vaccines
Associate Professor Eugene Maraskovsky
CSL Limited, Australia
9.30amSimple synthetic lipid structures target vaccine cargos to dendritic cells
Associate Professor David Jackson
National Health and Medical Research Council of Australia, University of Melbourne
10.00am Multiepitope vaccines for the prevention of herpesvirus associated diseases
Professor Rajiv Khanna
Australian Centre for Vaccine Development, Queensland Institute of Medical Research

SESSION 5: Rational design and regulatory issues of immunotherapeutic vaccines

Chair: Professor Peter Colman, FAA, FTSE
Structural Biology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne

11.00amComputer-driven vaccine design: From concept to reality
Dr Anne De Groot
Epivax Inc; Brown University Center for Genomics and Proteommics, USA
11.30pmStructural biology studies of infectious diseases: From AIDS to SARS to bird fl
Professor Zihe Rao
Nankai University, Tianjin, China
12.00pmImmunotherapy for HIV
Professor Stephen Kent
Department of Microbiology and Immunology, University of Melbourne

SESSION 6: Vaccine development and deployment: non-technical constraints

Chair: Professor Kenneth K Wu
National Health Research Institutes, Taiwan

2.00pmTransfer of technology as a solution to vaccine access?
Dr Luc Hessel
Sanofi Pasteur MSD, Lyon, France
2.30pmThe downstream self-assembly bioprocessing of virus-like particles
Professor Anton Middelberg, FTSE
Centre for Biomolecular Engineering, University of Queensland

SESSION 7: Vaccine procurement, distribution and delivery in the developing world

Chair: Ms Beth Slatyer
Australian Agency for International Development (AusAID), Canberra

3.30pmNew approaches to evaluating vaccine herd protection: Implications for future trials of vaccines against enteric infections
Dr John Clemens
International Vaccine Institute, South Korea
4.00pmDelivering the promise: New markets, new money and new models of development aid
Dr Julian Lob-Levyt
Global Alliance for Vaccines and Immunization, Switzerland

CONFERENCE DINNER

7.00pmDinner speaker
Dr Norman Swan
Science Unit, ABC Radio National

FRIDAY 11 APRIL

SESSION 8: Immune regulation and strategies to identify protective responses

Chair: Professor Graham Mitchell, FAA, FTSE
Foursight Associates, Melbourne

8.45amFriday Plenary Address
A decade of progress in global immunisation
Sir Gustav Nossal, FAA, FTSE
The University of Melbourne
9.30am Tumour vaccine cell therapy to overcome tumour escape mechanisms
Professor Takashi Nishimura
Institute for Genetic Medicine, Hokkaido University, Japan
10.00amUsing novel adjuvants to improve vaccine performance
Dr Nathalie Garçon
GlaxoSmithKline Biologicals, Belgium
11.00amAccelerating vaccine discovery for multiple pathogens using ORFeome screening technologies
Associate Professor David Sinclair
Department of Pathology, Harvard Medical School, Boston, USA
11.30amGenerating protective immunity to pathogen infections: Antigen presentation and vaccine approaches
Dr Gabrielle Belz
Division of Immunology, The Walter and Eliza Hall Institute of Medical Research, Melbourne
12.00pmStimulating subsets of T cells with cytokine/antibody complexes
Professor Jonathan Sprent, FAA
Immunology and Inflammation Research Programme, Garvin Institute of Medical Research, Sydney
 Closing remarks
Professor Ian Frazer, FAA, FTSE
Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland